Sunshine Biopharma, Inc.

NasdaqCM:SBFM

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🧬 Biotechnology

🔬 Clinical Trials

🏬 Consumer Packaged Goods

🌿 Fertilizers

Location

Canada

Market Cap

USD 6.56 M

Share Price

USD 1.44

Avg Daily Volume

1,439,153

Change (1 day)

-2.70%

Change (1 year)

-79.13%

Change (YTD)

-52.00%

Sunshine Biopharma, Inc. EBITDA for the year ending December 31, 2024: USD -5.15 M

Sunshine Biopharma, Inc. EBITDA is USD -5.15 M for the year ending December 31, 2024, a 34.78% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Sunshine Biopharma, Inc. EBITDA for the year ending December 31, 2023 was USD -3.82 M, a -85.54% change year over year.
Sunshine Biopharma, Inc. EBITDA for the year ending December 31, 2022 was USD -26.45 M, a 118.66% change year over year.
Sunshine Biopharma, Inc. EBITDA for the year ending December 31, 2021 was USD -12.10 M, a 364.85% change year over year.
Sunshine Biopharma, Inc. EBITDA for the year ending December 31, 2020 was USD -2.60 M, a 174.35% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqCM: SBFM

Sunshine Biopharma, Inc.

CEO	Dr. Steve N. Slilaty Ph.D.
IPO Date	Feb. 15, 2022
Location	Canada
Headquarters	6500 Trans-Canada Highway
Employees	52
Sector	🏥 Health Care
Industries Pharmaceuticals 🧬 Biotechnology 🔬 Clinical Trials 🏬 Consumer Packaged Goods 🌿 Fertilizers

Description

Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.